Compare LYFT Inc (LYFT) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LYFT Inc vs Natera Inc. Common Stock — how do they compare? LYFT Inc trades at $16.42 (market cap $6.20B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 9.2× LYFT Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, LYFT Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold LYFT Inc for 48 Days and Natera Inc. Common Stock for 0 Days on average.
| LYFT | NTRA | |
|---|---|---|
Market Cap | $6.20B | $57.03B |
Volume | 12,306,511 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $24.57 | $425.64 |
52-Week Low | $12.65 | $179.42 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | $5.67B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lyft trades at $16.38, up 1.68% with a bullish technical signal. The company shows strong profitability with 45.52% gross margins and 42.32% net income margin, though recent earnings missed expectations. Positive developments include European expansion and a major partnership with Sphere Entertainment. Cash flow improved significantly to $891M in 2025 from negative levels in prior years.
Lyft presents a mixed outlook with strong fundamentals but execution risks. The stock trades below analyst consensus target of $18.07, offering potential upside. Key risks include regulatory challenges from the $272.5M driver classification settlement and competitive pressures. Institutional sentiment leans cautious with 58% hold ratings despite improving financial metrics.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
